Adakveo Injection
Product Images NDC 0078-0883

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Adakveo (NDC 0078-0883). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Preparation And Administration (Seg101 01)

An equation diagram showing the formula to calculate the volume (mL) of ADAKVEO injection to administer. It specifies multiplying patient's body weight (kg) by the prescribed dose (5 mg/kg), then dividing by the concentration of ADAKVEO (10 mg/mL).*

FDA Label Image

Principal Display Panel Ndc 0078-0883-61 Rx Only Adakveo® (crizanlizumab-tmca) Injection 100 mg/10 mL (10 mg/ml) For Intravenous Infusion After Dilution. 1 Single-dose Vial. Discard Unused Portion. Novartis (Seg101 02)

ADAKVEO (crizanlizumab-tmca) Injection 100 mg/10 mL (10 mg/mL) carton label for intravenous infusion after dilution. The label states it contains 1 single-dose vial, to discard unused portion, and instructions on storage at 2°C to 8°C. It is manufactured by Novartis Pharmaceuticals Corporation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.